MedImmune Inc. (MEDI) is one of a handful of companies that have succeeded in establishing a fully-integrated biotech company. With its 60-person sales staff already selling RespiGam (Respiratory Syncytial Virus Immune Globulin), MEDI had intended to handle U.S. distribution of MEDI-493, a second generation monoclonal antibody to prevent RSV disease in infants. So it was surprising to see MEDI grant U.S. co-promotion rights to MEDI-493 as part of its deal with Abbott Laboratories last week.

The explanation, according to President and COO David Mott, lies in MEDI's desire to access Abbott's strong international position and in the persistence of Abbott's Ross Products